Natco Pharma Gets Legal Clearance to Manufacture Semaglutide

Natco Pharma semaglutide plans received a major boost after the company secured regulatory clearance from the High Court to manufacture and export the drug to select global markets.

The decision is a vital milestone of Natco Pharma on its way to the fast-growing diabetes and obesity treatment medical field.

According to the court order, Natco Pharma is now permitted to initiate manufacture of semaglutide which is a common treatment to type 2 diabetes and chronic weight management. The decision also enables the company to sell the drug to some foreign markets but the countries to be sold have not been revealed as per a report published by Scanx.

Also Read: Role of Wellness in Corporate & Community Health

Semaglutide is part of the GLP-1 receptor agonist group of medications that have experienced a significant demand in the global market following the positive clinical results in blood sugar and weight loss in the long term. This approval will allow Natco Pharma semaglutide production to proceed, which will enable it to enter into a highly competitive and fast growing global market.

The acquisition enhances the production capacity of Natco Pharma and enhances its market niche in chronic diseases, particularly in metabolic diseases. It is also an indication that the company is willing to expand its revenue base beyond the domestic market.

Due to the recent granting of the permission to export, Natco pharma can venture into the overseas market, provided that the regulatory authorities in the respective countries allow it to do so. The relocation is in line with an overall company strategy of increasing its presence in the world in sophisticated and high need therapeutic fields.